A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
A phase 2 trial of ICP-248 in mantle cell lymphoma, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.
Overview
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06) is a phase 2 interventional study registered as NCT07082686 by Beijing InnoCare Pharma Tech Co., Ltd., with 75 participants planned, started 2025-08-21 and due to reach its primary completion in 2027-12. Interventions recorded: ICP-248. Conditions listed: Relapsed or Refractory Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.
Setting
A Single-arm, Multi-center, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Phase
Phase 2
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd.
Registry
Enrolled
75